Global G-CSF Biosimilars Market Size study, by Type (Human Growth Hormone, Erythropoietin, Monoclonal Antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor), By Application (Blood Disorders, Oncology Diseases, Chronic and Autoimmune Diseases, Growth Hormone Deficiencies) and Regional Forecasts 2018-2025
-
Product Code:
RP-ID-10074177 -
Published Date:
21 Oct 2022 -
Region:
Global
-
Pages:
200 -
Category:
Healthcare & Pharmaceuticals -
Publisher:
Pub-ID-14
Impact Analysis on the Growth of Market
Inflation and Looming Recession to Haunt Businesses:
In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.
....
The Research Report is Updated with 2022 Base Year, 2023 Estimated year and Forecast till 2035 with Market Insights.
With the dip in global production, the GDP has contracted in 2020 and impacted the market across the world. Upon placing a Sample Request, you will receive an updated report with 2022 as base year, 2023 as estimated year and forecast to 2035. This will have market drivers, recovery rate in the market, insights and competitive analysis.
Market Overview:
Translate Report
Global G-CSF Biosimilars Market to reach USD XX billion by 2025.
Global G-CSF Biosimilars Market valued approximately USD XX billion in 2017 is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2018-2025. The G-CSF Biosimilars Market is continuously growing across the world over the coming years. Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein containing 174 amino acids with a molecular weight of about 20000. GCSF stimulates granulocyte production in BM suppressed by chemotherapy and radiotherapy and reduces infections in cancer patients. It can induce terminal maturation of myeloid leukemia cells, resulting in complete hematologic and cytologic remission, and can suppress self-renewal. It is useful in patients with AIDS or leukemic relapse after allogeneic BM transplantation. Increasing aging population, growing incidence of chronic diseases and rising healthcare expenditure are the substantial driving factors of the market across the globe. In addition, growing acceptance due to their cost-effectiveness is also boosting the market growth over the upcoming years. Furthermore, patent expiry of biologic products is the major factor which creating numerous opportunity in the market over the coming years. However, complications associated with manufacturing of G-CSF biosimilars are the factors which limiting the market growth of G-CSF Biosimilars over the coming years. The regional analysis of Global G-CSF Biosimilars Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World.
The major market player included in this report are:
• Pfizer
• Novartis
• Roche
• Merck & Co.
• Sanofi
• Johnson & Johnson
• Gilead Science
• GlaxoSmithKline
• AbbVie
• Amgen
• AstraZeneca
• Bayer
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
 Human Growth Hormone
 Erythropoietin
 Monoclonal Antibodies
 Insulin
 Interferon
 Granulocyte-Colony Stimulating Factor
By Application:
 Blood Disorders
 Oncology Diseases
 Chronic and Autoimmune Diseases
 Growth Hormone Deficiencies
By Regions:
 North America
o U.S.
o Canada
 Europe
o UK
o Germany
 Asia Pacific
o China
o India
o Japan
 Latin America
o Brazil
o Mexico
 Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2015, 2016
Base year – 2017
Forecast period – 2018 to 2025
Target Audience of the Global G-CSF Biosimilars Market in Market Study:
 Key Consulting Companies & Advisors
 Large, medium-sized, and small enterprises
 Venture capitalists
 Value-Added Resellers (VARs)
 Third-party knowledge providers
 Investment bankers
 Investors
Geography Analysis:
The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:
- North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys & Opportunity Outlook
- Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook
.
Please enter your personal details below
Novartis
Roche
Merck & Co.
Sanofi
Johnson & Johnson
Gilead Science
GlaxoSmithKline
AbbVie
Amgen
AstraZeneca
Bayer